文献速递肿瘤 PET/CT神经核医学

「终极三联PET」:同一患者中68Ga-DOTATATE、18F-FDG与18F-Fluciclovine PET/CT表现

The "Ultimate Triple PET": 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2022-01-01

71岁男性,有类癌和前列腺腺癌病史,因新发纵隔淋巴结肿大行68Ga-DOTATATE PET/CT,显示新发类癌转移但纵隔淋巴结无摄取;18F-FDG PET/CT用于评估心脏和纵隔结节病,显示无心脏结节病但可能纵隔结节病;18F-Fluciclovine PET/CT用于评估前列腺转移,显示已知前列腺癌。三种不同PET放射性药物在195天内揭示了同一患者的三种不同病理过程。

要点

  • 68Ga-DOTATATE PET/CT显示新发类癌转移,但纵隔淋巴结无摄取。
  • 18F-FDG PET/CT提示可能纵隔结节病,无心脏结节病。
  • 18F-Fluciclovine PET/CT显示已知前列腺癌。

核心结论

  • 三种不同PET放射性药物在195天内揭示了同一患者的三种不同病理过程,展示了核医学诊断的能力。

研究设计与样本

  • 71岁男性,有类癌和前列腺腺癌病史,因新发纵隔淋巴结肿大行68Ga-DOTATATE PET/CT,后行18F-FDG PET/CT和18F-Fluciclovine PET/CT。

主要发现

  • 68Ga-DOTATATE PET/CT显示新发类癌转移,但纵隔淋巴结无摄取。
  • 18F-FDG PET/CT显示无心脏结节病,但可能纵隔结节病。
  • 18F-Fluciclovine PET/CT显示已知前列腺癌。

临床怎么用

  • 在多发肿瘤病史患者中,针对不同临床问题可选择不同PET放射性药物以区分不同病理过程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent 68Ga-DOTATATE PET/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. 18F-FDG PET/CT was performed to evaluate for cardiac and mediastinal sarcoidosis, revealing a lack of cardiac sarcoidosis, but probable mediastinal sarcoidosis. 18F-Fluciclovine PET/CT was then performed for possible prostate metastases, revealing the patient's known prostate cancer. Three different PET radiopharmaceuticals revealed 3 different processes in a single patient within a 195-day period, demonstrating the power of nuclear medicine diagnostics.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. McClenathan M, Peacock JG. The "Ultimate Triple PET": 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer. Clin Nucl Med. 2022. PMID: 34392283. doi:10.1097/RLU.0000000000003853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。